Profil bibliographique

Funda Yılmaz

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

9Publications signalées

70Citations signalées

2Affiliations récentes

Les institutions déclarées

Ankara Onkoloji Eğitim ve Araştırma Hastanesi Sağlık Bilimleri Üniversitesi

Les domaines associés

Advanced Breast Cancer TherapiesBreast Cancer Treatment StudiesCancer-related Molecular PathwaysHER2/EGFR in Cancer ResearchChronic Lymphocytic Leukemia Research

Les publications récentes

Accès ouvert 2025 article OpenAlex

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Seda Kahraman, Enes Erul, Özge Gümüşay, Deniz Can Güven et autres

tr (code pays fourni par la source)

4 citations Clinical Breast Cancer

Accès ouvert 2025 article OpenAlex

Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemi

Seda Kahraman, Mutlu HIZAL, Özge Gümüşay, Gül Başaran et autres

Somalie, ag, tr, kz, jp, co, gb (code pays fourni par la source)

0 citations DergiPark (Istanbul University)

Accès ouvert 2024 article OpenAlex

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

Seda Kahraman, Mutlu Hızal, Burçin Çakan Demirel, Deniz Can Güven et autres

tr (code pays fourni par la source)

6 citations BMC Cancer

Accès ouvert 2024 article OpenAlex

The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer

Hasan Çağrı Yıldırım, Mustafa Büyükkör, Gözde Kavgacı, Buket Şahin Çelik et autres

tr (code pays fourni par la source)

2 citations Medicine

Accès ouvert 2024 preprint OpenAlex

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Seda Kahraman, Enes Erul, Özge Gümüşay, Cihan Erol et autres

tr, co, kz (code pays fourni par la source)

0 citations SSRN Electronic Journal

2023 article OpenAlex

Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data

Osman Sütçüoğlu, Akif Doğan, Funda Yılmaz, Ahmet Bilgehan Şahin et autres

tr (code pays fourni par la source)

4 citations Pancreas

Accès ouvert 2023 article OpenAlex

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Seda Kahraman, Enes Erul, Mustafa Seyyar, Özge Gümüşay et autres

tr (code pays fourni par la source)

26 citations Future Oncology

Accès ouvert 2023 erratum OpenAlex

Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Cengiz Karaçin, Berna Öksüzoğlu, Ayşe Demirci, Merve Keskinkılıç et autres

tr (code pays fourni par la source)

5 citations BMC Cancer

Accès ouvert 2023 article OpenAlex

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Cengiz Karaçin, Berna Öksüzoğlu, Ayşe Demirci, Merve Keskinkılıç et autres

tr (code pays fourni par la source)

23 citations BMC Cancer

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.